Verification evidence is still being completed.
PDF / print export
BioArctic
Stockholm, Sweden
- Verified lead
- Gunilla Osswald
- Lead status
- STATUS: VERIFIED MARCH 2026
- Leadership verification
- CEO
- 2026 technical specialization
- Neurodegeneration, Alzheimer's Disease, Parkinson's Disease, Antibody Therapeutics, and CNS Drug Development
- Review cycle
- May 2026
- Full address
- Warfvinges vag 35, 112 51 Stockholm, Sweden
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Official BioArctic contact page confirming the Stockholm address.
- Editorial note
- BioArctic is published because official company materials confirm current leadership, Stockholm operating address, and a strong neurodegeneration therapeutics platform.
Neurodegeneration, Alzheimer's Disease, Parkinson's Disease, Antibody Therapeutics, and CNS Drug Development
Official leadership disclosure, Official Stockholm contact disclosure, Clinical-stage therapeutics platform claim
BioArctic is published because official company materials confirm current leadership, Stockholm operating address, and a strong neurodegeneration therapeutics platform.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated02 Jun 2026, 01:40
Company profile · Stockholm, Sweden
BioArctic
Neurodegeneration, Alzheimer's Disease, Parkinson's Disease, Antibody Therapeutics, and CNS Drug Development · Clinical-stage biotech platform
BioArctic runs cns therapeutics development, antibody program development, and clinical neurodegeneration programs in Stockholm, Sweden.
- Lead
- Gunilla Osswald (verified ↗)
- Address
- Warfvinges vag 35, 112 51 Stockholm, Sweden (source ↗)
- Compliance
- Not yet on record
- Last reviewed
- 21 Mar 2026 (2mo ago)
- Scale
- Clinical-stage biotech platform
- Capabilities
- CNS Therapeutics Development · Antibody Program Development · Clinical Neurodegeneration Programs
- Founded
- 2003
- Headcount
- 51-200
- Company page (open ↗)
Clinical profileSTATUS: VERIFIED MARCH 2026
Gunilla Osswald
CEO
Full addressWarfvinges vag 35, 112 51 Stockholm, Sweden
Site coordinatesVerification evidence is still being completed.
Review cycleMay 2026
Clinical-stage biotech platform
Stockholm, Sweden. Neurodegeneration, Alzheimer's Disease, Parkinson's Disease, Antibody Therapeutics, and CNS Drug Development. Review completed on 21 Mar 2026.
Swedish corporate and clinical-development oversight
Official leadership disclosure, Official Stockholm contact disclosure, Clinical-stage therapeutics platform claim
Neurodegeneration, Alzheimer's Disease, Parkinson's Disease, Antibody Therapeutics, and CNS Drug Development
BioArctic is published because official company materials confirm current leadership, Stockholm operating address, and a strong neurodegeneration therapeutics platform.
Editorial note
BioArctic is published because official company materials confirm current leadership, Stockholm operating address, and a strong neurodegeneration therapeutics platform.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleMarch 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
CNS Therapeutics Development
Antibody Program Development
Clinical Neurodegeneration Programs
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
Therapeutics R&D workflow
Clinical program infrastructure
CNS drug-development systems
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
21 Mar 2026: Executive identity confirmed via official management disclosure.
21 Mar 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is BioArctic located?
- BioArctic operates from Warfvinges vag 35, 112 51 Stockholm, Sweden, Stockholm, Sweden.
- Who runs BioArctic?
- BioArctic is led by Gunilla Osswald, CEO. Verified 21 Mar 2026.
- What does BioArctic do?
- BioArctic runs cns therapeutics development, antibody program development, and clinical neurodegeneration programs in Stockholm, Sweden. Core capabilities: CNS Therapeutics Development, Antibody Program Development, Clinical Neurodegeneration Programs.
Editorial context
Related technical briefs
Briefs that name Stockholm as a covered market or city.